TY  - JOUR
AU  - Giraldo, Pilar
AU  - Andrade-Campos, Marcio
AU  - Alfonso, Pilar
AU  - Irun, Pilar
AU  - Atutxa, Koldo
AU  - Acedo, Antonio
AU  - Barez, Abelardo
AU  - Blanes, Margarita
AU  - Diaz-Morant, Vicente
AU  - Fernández-Galán, Ma Angeles
AU  - Franco, Rafael
AU  - Gil-Cortes, Cristina
AU  - Giner, Vicente
AU  - Ibañez, Angela
AU  - Latre, Paz
AU  - Loyola, Ines
AU  - Luño, Elisa
AU  - Hernández-Martin, Roberto
AU  - Medrano-Engay, Blanca
AU  - Puerta, José
AU  - Roig, Inmaculada
AU  - de la Serna, Javier
AU  - Salamero, Olga
AU  - Villalón, Lucia
AU  - Pocovi, Miguel
PY  - 2016
DO  - 10.1016/j.bcmd.2016.10.017
UR  - http://hdl.handle.net/10668/10599
T2  - Blood cells, molecules & diseases
AB  - We report data from a prospective, observational study (ZAGAL) evaluating miglustat 100mg three times daily orally. in treatment-naïve patients and patients with type 1 Gaucher Disease (GD1) switched from previous enzyme replacement therapy (ERT)....
LA  - en
KW  - Efficacy
KW  - Gaucher disease type 1
KW  - Maintenance
KW  - Miglustat
KW  - Safety
KW  - 1-Deoxynojirimycin
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Female
KW  - Follow-Up Studies
KW  - Gaucher Disease
KW  - Glycoside Hydrolase Inhibitors
KW  - Humans
KW  - Liver
KW  - Male
KW  - Middle Aged
KW  - Organ Size
KW  - Prospective Studies
KW  - Spleen
KW  - Young Adult
TI  - Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
TY  - research article
VL  - 68
ER  -